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Heparan sulfate (HS), dermatan sulfate (DS), and heparin are natural glycosaminoglycans (GAG), which are linear 
polysaccharides, heterogeneous in both sequence and length.1 
GAGs carry out many functions in the body and can influ-
ence numerous physiological processes. The most notable is 
control of coagulation, but GAGs also affect lipid metabolism, 
inflammation, cell attachment, migration, invasion, and differ-
entiation.1 GAGs play a key role as anticoagulants, preventing 
coagulation from occurring when it is not required. GAGs are 
responsible for interacting with and enhancing the actions of 
several serpins; HS and heparin primarily bind to antithrom-
bin and DS to heparin cofactor II (HCII).2 However, HS and 
heparin can also interact with HCII.3 The principal activities 
of antithrombin are to inhibit both thrombin and activated fac-
tor X, 2 important proteins of the coagulation cascade.2 HCII 
inhibits thrombin but not activated factor X.3
When coagulation is necessary, for example, after tissue 
injury, GAGs need to be neutralized to enable clot formation.4 
This includes endogenous GAGs during normal clotting and 
heparin-based drugs, which are used clinically to treat a range 
of thrombotic disorders, including venous thromboembolism 
and acute coronary syndrome.5 This review will describe current 
knowledge concerning the principal properties of key proteins 
involved in GAG neutralization, the mechanisms by which they 
interact with GAGs, and how this affects the coagulation process.
Synthesis of GAGs
The saccharide sequences of HS and heparin consist predomi-
nantly of 2 trisulfated disaccharide motifs. The first motif 
represents N-sulfated glucosamine linked to iduronic acid 
(IdoA) and the other N-acetylated glucosamine (GlcNAc) 
linked to glucuronic acid (GlcA).1 The sequence in which these 
motifs occur results from enzyme-catalyzed modifications.6–8 
Heparin and HS differ in the ratio by which these 2 motifs 
are present within the GAG; heparin is defined as containing 
at least 70% of the first motif.8 The sequences of DS consist 
of 2 different motifs. These are N-acetylated galactosamine 
(GalNAc) linked to IdoA and GalNAc linked to GlcA.1 The 
sequences of the saccharide groups that form HS, heparin, and 
DS are shown in Figure 1.1 Some GAGs carry specific binding 
sequences for antithrombin and HCII, and those can greatly 
enhance the efficiency of the binding to those serpins.3,9,10
The length of the GAGs, sulfation percentage, and saccha-
ride sequence vary depending on the tissue in which they are 
generated because of cell type–specific expression of GAG-
synthesizing enzymes (as summarized in Refs. Carlsson and 
Kjellen9 and Silbert and Sugumaran11). Synthesis begins by 
formation of a tetrasaccharide, GlcA–galactose–galactose–
xylose, which forms the linkage region. For HS and heparin, 
the next saccharide to attach is GlcNAc, which is performed 
by a unique GlcNAc transferase-I enzyme that plays no fur-
ther part in the synthesis. For DS, it is a GalNAc transferred by 
a GalNAc transferase enzyme. The chain is then further elon-
gated by transferase enzymes, which add alternating GlcA 
and either GlcNAc or GalNAc. As the GAG chain grows, it 
is modified by the action of various enzymes, which include 
(1) the N-sulfation of GlcNAc to N-sulfated glucosamines by 
N-deacetylase/N-sulfotransferase; (2) the epimerization of 
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D-GlcA saccharides, adjacent to N-sulfated glucosamines or 
GalNAc 4-S, to L-IdoA by C5-epimerases; (3) the 6-O-sulfation 
of GlcNAc and GalNAc by 6-O-sulfotransferases; (4) the 
4-O-sulfation of GalNAc by 4-O-sulfotransferases; and (5) 
the 2-O-sulfation of IdoA (and in to a lesser extent GlcA) by 
2-O-sulfotransferases.
In addition, a less frequent but important modifica-
tion is the sulfation in the C3 position of GlcNAc by 
3-O-sulfotransferase, which forms part of the antithrombin-
binding site.9 This antithrombin-binding site on HS and hepa-
rin is a pentasaccharide sequence. On DS, the HCII-binding 





−).3 The natural binding 
sequences for HCII on HS and heparin have not yet been con-
firmed, but 2 possible HS hexasaccharide structures have been 
predicted based on an in silico study, and enhancement of 
HCII inhibition of thrombin has been confirmed after synthe-
sis of the hexasaccharides.10 The serpin-binding sites on HS, 
DS, and heparin are shown in Figure 2.
Distribution of HS, DS, and Heparin and Their 
Anticoagulant Actions
HS and DS are synthesized by many cell types and tissues, 
whereas heparin is only synthesized in mast cells.12 HS is 
mainly localized at the surface of cells and the endothelium,1 
while DS is present in the extracellular matrix of several types 
of tissue including skin, bone, cartilage, and the vasculature.1 
The surface of the endothelium is made of a layer of glyco-
proteins and proteoglycans called the endothelial surface 
layer (ESL), which is made of a core protein bound to one 
or several GAG chains. The ESL varies in thickness depend-
ing on its location: ranging from around 0.5 to 3 μm in small 
arteries ≤4.5 μmol/L in carotid arteries.13 ESL thickness is 
also influenced by oxidative stress and atherosclerosis.13 The 
composition of the ESL is dynamic; ESL proteins undergo a 
high rate of turnover, and the specific GAGs that are present 
(and their sulfation pattern) also change over time. Turnover 
and GAG-binding specificity depends on the activation of the 
endothelial cells by local chemokine stimuli.13 A summary 
of proteoglycans present in the ESL and their GAG-binding 
properties are provided in Table 1.
An important aspect of the ESL is its anticoagulant prop-
erties. Indeed, ESL GAGs bind several anticoagulant proteins, 
antithrombin, HCII but also thrombomodulin and tissue fac-
tor pathway inhibitor. The endothelial anticoagulant HS, for 
example, is saturated with antithrombin (the K
d
 for this inter-
action is 15 nmol/L, while antithrombin plasma concentration 
is 3.5 μmol/L).14 GAG binding to serpins induces a change 
in the conformation of the reactive center loop of the serpin, 
thus enhancing the inhibitory activity of the protein.2 Longer 
chain GAGs are specifically required to enhance the binding 
of antithrombin to thrombin but not to activated factor X.2 
This is also the case for HCII and thrombin, although some 
thrombin inhibition still occurs in the presence of shorter 
chain GAGs (Figure 3).3
The main GAG in the vasculature is HS, which represents 
50% to 90% of the total GAG content.13 Next is chondroitin 
sulfate, of which DS is a subtype.13 Although all membrane-
associated HS can bind antithrombin, only a small fraction of 
these molecules (0.5%–10%) possess the antithrombin-bind-
ing sequence necessary to bind with high specificity under 
physiological conditions.14,15 Approximately 95% of antico-
agulant HS is present in the subendothelial matrix and is only 
in contact with blood when injury occurs.14,15 In the case of 
heparin, ≈30% of molecules possess the antithrombin-binding 
sequence.16 The exact proportion of HS and heparin that can 
bind HCII is unknown, but a much greater quantity of the 
GAG is required to overcome HCII-mediated inhibition than 
with antithrombin.3 Vascular DS is located in the deeper layer 
of the vessel walls and in the subendothelium and is only able 
to interact with blood proteins during injury.3 Roughly 5% of 
Nonstandard Abbreviations and Acronyms
DS dermatan sulfate
ESL endothelial surface layer











PF4 platelet factor 4
UFH unfractionated heparin
A B C D
Figure 1. The principal disaccharide motifs that constitute heparin, heparan sulfate, and dermatan sulfate. A, Heparin and heparan sul-
fate motif 1, iduronic acid-N-sulfated glucosamine. B, Heparin and heparan sulfate motif 2, glucuronic acid-N-acetylated glucosamine. 
C, Dermatan sulfate motif 1, iduronic acid-N-acetylated galactosamine. D, Dermatan sulfate motif 2, glucuronic acid-N-acetylated 
galactosamine.
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disaccharide unit, of which 3 consecutive repeats are required 
to form the HCII high-affinity-binding sequence. Chains con-
taining only part of the total sequence still bind HCII but with 
a lower affinity.3
The importance of heparin release from mast cells at sites 
of injury is controversial. Some studies have been unable to 
detect heparin in plasma,17,18 while Engelberg and Dudley19 
(1961) reported that each liter of plasma contains 1.0 to 2.4 
mg of heparin (ca. 66–160 nmol/L). To ascertain the impor-
tance of endogenous anticoagulant GAG in vivo, 2 knockout 
mice models have been studied. Hemostasis in mice lacking 
3-O-sulfotransferase-1 (the enzyme involved antithrombin-




Figure 2. Anticoagulant glycosaminoglycans-binding sequence for antithrombin and heparin cofactor II. A, The main heparin and heparan 
sulfate sequence for binding to antithrombin. B, The main dermatan sulfate sequence for binding to heparin cofactor II. C, Two heparin 
and heparan sulfate sequences for binding to heparin cofactor II. The sequences were predicted in silico, and their ability to neutralize 
those two glycosaminoglycans was confirmed in vitro.10 GlcA indicates glucuronic acid; and IdoA, iduronic acid.
Table 1. Proteoglycans Present in the ESL and Their GAG-Binding Properties13
Core Protein Name Number of Subtypes
Type of GAG Chains 
Bound
Number of GAG Chains 
Bound
Attached to the ESL or 
Secreted Into the Plasma Notes
Syndecan 4 HS and chondroitin 
sulfate
5 Attached  
Glypican 6 HS and chondroitin 
sulfate
3 Attached Main anticoagulant 
proteoglycan
Mimecan 1 Keratan sulfate 2–3 Secreted  
Perlecan 1 HS and chondroitin 
sulfate
3 Secreted  
Biglycan 1 Chondroitin sulfate 
and DS
2 Secreted  
Versican 1 Chondroitin sulfate 
and DS
10–30 Secreted  
Decorin 1 Chondroitin sulfate 
and DS
1 Secreted  
DS indicates dermatan sulfate; ESL, endothelial surface layer; GAG, glycosaminoglycans; and HS, heparan sulfate.
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of the gene encoding this enzyme, where a strong proco-
agulant challenge failed to reveal a latent procoagulant 
state.14 This suggests that either the anticoagulant activity of 
HS is not essential for normal homeostasis in vivo or that 
there is redundancy between sulfotransferase-1 and one of 
its isotypes (eg, 3-O-sulfotransferase-5). It is also possible 
that antithrombin expression is increased in these animals 
to compensate for the loss of the enzyme.14,20 In addition, 
HS lacking the canonical antithrombin-binding sequence 
can still bind antithrombin but exhibits reduced affinity 
compared with HS with the binding sequence present. This 
HS has antithrombin activity but not anti–activated factor 
X activity.14 Mice engineered to lack the N-deacetylase/N-
sulfotransferase 2 enzyme (encoded by the NDST2 gene), 
which is involved in heparin, but not HS, synthesis have 
also been studied.21,22 No coagulatory defects were reported 
in these animals. However, these studies did not specifically 
examine clot parameters.18,21,22
Use of Heparin-Based Drugs
Clinically, heparins are the main anticoagulants adminis-
tered for several conditions, including venous thromboem-
bolism, acute coronary syndrome, cardiopulmonary bypass, 
and hemodialysis.7 Naturally occurring heparins vary in size 
from 3 to 30 kDa, with an average of 15 kDa and when used 
therapeutically are termed unfractionated heparins (UFH). 
UFH can be fully neutralized by protamine sulfate when 
there is a risk of bleeding.23 Low-molecular-weight heparins 
(LMWH) are artificially derived from UFH by depolymeriza-
tion or fractionation,6 and their use has now replaced that of 
UFH for many clinical applications. LMWHs are associated 
with fewer side effects (notably reduced prevalence/severity 
of osteoporosis and heparin-induced thrombocytopenia) and 
have a more predictable dose–response profile because they 
associate less with plasma proteins.5 They also have a lon-
ger half-life and thus require less frequent administration. It 
should be noted, however, that LMWHs are more expensive, 
can only be partially neutralized by protamine sulfate, and 
cannot be cleared from patients having renal insufficiency 
(and in such cases they will accumulate over time).4,7 A sum-
mary of US- and EU-approved heparin-based drugs are pro-
vided in Table 2. These also include the synthetic analogue 
of heparin, Fondaparinux—which is based on the antithrom-
bin-binding sequence. This drug is thought to exhibit fewer 
side effects than LMWH drugs because of having a higher 
specificity for antithrombin. Importantly, Fondaparinux can-
not be neutralized (although injections of recombinant fac-
tor VII may be effective to stop bleeding) and can only be 
cleared by the renal system. As with LMWH, it is therefore 
contraindicated in patients having renal disease.5 Another 
drug, danaparoid is a mixture of HS, DS, and chondroitin 
sulfate and is used in some countries for the treatment of 
heparin-induced thrombocytopenia.24
The binding of endogenous GAGs to proteins is influenced 
by various factors, including the degree of sulfation, which 
facilitates electrostatic interactions between the GAG and the 
respective protein. Heparin is generally more sulfated than 
HS, and DS less so.25 A possible clinical consequence of such 
interactions is that administration of heparin-based drugs can 
potentially displace many of the proteins bound to GAGs in the 
A
B
Figure 3. Interactions of glycosaminoglycans (GAGs) with (A) antithrombin (AT), thrombin, and activated coagulation factor X (FXa) and 
(B) heparin cofactor II (HCII) and thrombin. The GAGs bind AT and HCII via specific binding sequences, a pentasaccharide or a hexasac-
charide sequence, respectively. This binding induces a conformational change in the serpins, which makes the reactive center loop more 
accessible for their substrates. A simultaneous binding to AT and thrombin requires a chain length of minimum 18 saccharides while bind-
ing to HCII, and thrombin requires 24 saccharides.
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ESL. This may result in an increase in the availability of GAGs 
for interaction with clot-regulating proteins (see Figure 4).26 
Such a mechanism would alter the half-life and kinetic proper-
ties of these agents. The associated difficulties in predicting 
such events could result in excessive bleeding in patients.
Heparin-based drugs are generally best for acute manage-
ment and prophylaxis of deep vein thrombosis and pulmonary 
embolism and for prophylaxis during and after orthopedic 
and general surgeries.5,27,28 Current NICE guidelines from the 
United Kingdom suggest that, when prophylaxis is required, 
offering patients either Fondaparinux or LMWH (no distinc-
tion is made between the different LMWHs) is usually best 
practice. However, UFH, despite its associated side effects, 
can be advised when rapid intervention is needed, in individu-
als with an increased risk of bleeding or those who are hav-
ing renal failure.28 Whether LMWH or UFH are administered 
for venous thromboembolism prophylaxis is highly variable, 
and patients have not always received the recommended treat-
ment. The 2007 study—IMPROVE (the International Medical 
Prevention Registry on Venous Thromboembolism), which 
examined hospitalized patients at risk of venous thromboem-
bolism across 12 countries—found that out of all patients who 
should have received prophylaxis (in accordance to the guide-
line recommendations at the time from the American College 
of Chest Physicians), 14% of patients in the United States 
received LMWH and 21% UFH. This preference is because 
of UFH being a lower cost drug. Across the other participating 
countries, where downstream costs were more likely to be con-
sidered, 40% of patients on average received LMWH and 9% 
UFH.29 From this, it is clear that practices for administration of 
prophylaxis are suboptimal, and stricter evidence-based guide-
lines in hospitals urgently need to be implemented.
GAG-Neutralizing Proteins Released During 
Injury and Coagulation
The ESL is a heterogeneous surface that can bind proteins 
and other molecules and is essential for the function of the 
endothelium.13 GAGs associated with the ESL are involved in 
numerous physiological processes: coagulation, lipid metabo-
lism, inflammation, cell attachment, migration, invasion, and 
differentiation.1 Receptors, enzymes, and their respective 
ligands/substrates can bind to vascular GAGs, causing a local-
ized rise in their concentration to impact on signaling or enzy-
matic modification. Fibroblast growth factors (FGF) notably 
need to bind to endothelial HS for functioning as this helps 
mediate FGF oligomerization, binding of FGFs to their cog-
nate receptors, and transport of FGF between cells and can act 
as an FGF reservoir.30 Proteins involved in regulating a vari-
ety of physiological processes have the ability to neutralize 
the anticoagulant activity of certain GAGs. A range of these 
proteins and their specific properties are listed in Table 3. 
Neutralization can be accomplished via different mecha-
nisms, and so particular neutralizing proteins may affect only 
certain GAG–serpin combinations (as described in Table 4). 
Some of these neutralizing proteins are present at high levels 
in blood plasma, but other common sources include activated 
platelets, activated neutrophils, and damaged cells (Figure 4). 
As important binding partners of GAGs, some growth fac-
tors have GAG-neutralizing properties. This is the case for 
FGF7, heparin affin regulatory peptide and, to a lesser extent, 
Table 2. US- and EU-Approved Heparin-Based Drugs, Their Major Side Effects, Contraindications, and Main Applications5–7,24
Drug Name Average Size, kDa Country Where Approved GAG Type Side Effects and Contraindications Applications
UFH 15 USA, Europe UFH Heparin-induced 
thrombocytopenia, osteoporosis
Venous thromboembolism, 
acute coronary syndrome, 
cardiopulmonary bypass, 
hemodialysis, patients with 
underlying bleeding risk, or in 
those with renal insufficiency
Enoxaparin 4.5 USA, Europe LMWH Some heparin-induced 
thrombocytopenia, only partial 
neutralization needed, risk of 




Dalteparin 6 USA, Europe LMWH
Tinzaparin 6.5 USA, Europe LMWH
Reviparin 3.9 Europe LMWH
Nadroparin 4.3 Europe LMWH
Bemiparin 3.6–3.8 Europe LMWH
Certoparin 3.8 Europe LMWH
Parnaparin 5 Europe LMWH
Danaparoid 5.5 Europe Mixture of HS, DS, and 
chondroitin sulfate
Some heparin-induced 
thrombocytopenia, risk of 
bleeding, renal insufficiency, or 
disease
Treatment of heparin-induced 
thrombocytopenia
Fondaparinux 1.7 USA, Europe Synthetic heparin 
analogue
Neutralization not possible, risk 
of bleeding, renal insufficiency, or 
disease
Treatment of heparin-induced 
thrombocytopenia
DS indicates dermatan sulfate; EU, European Union; GAG, glycosaminoglycans; HS, heparan sulfate; LMWH, low-molecular-weight heparin; UFH, unfractionated 
heparin; and US, United States.
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FGF1.31,32 FGF7 and heparin affin regulatory peptide are also 
upregulated during injury, thus giving GAGs a dual role in 
coagulation mediation and wound healing.32,33
Similar to FGF, chemokine and cytokine activity is 
directly linked to their ability to bind endothelial GAGs which 
can direct and enhance their actions. For example, GAGs can 
modulate the inflammatory response by binding cytokines 
and so preventing them from binding to cell surface receptors. 
Cleavage of those GAGs during inflammation releases cyto-
kines which in turn increases endothelial cells activation.13 
Such chemokines also reside in the α-granules of platelets 
and are released when these cells are activated. Their GAG-
binding ability has been linked to a dual role of GAG in wound 
healing. Among those is platelet factor 4 (PF4), an important 
GAG-neutralizing protein. It has been proposed that, when 
released, PF4 neutralizes the negative charge of GAGs at the 
surface of endothelial cells. This allows platelets (which pos-
sess a net negative charge at their surface) to associate with 
the endothelium to enhance thrombus formation.52 In addition, 
PF4 binds to nucleic acid (another type of polyanion) exposed 
by damaged cells. Heparin-induced thrombocytopenia, one of 
the significant secondary effects caused by heparin adminis-
tration, is induced by antibodies reacting to the presence of 
PF4–nucleic acid complexes.75
Another family of GAG-neutralizing proteins are pro-
teins involved in coagulation that are also secreted by acti-
vated platelets at site of injury. Among those are vitronectin, 
fibronectin, and fibrinogen. Vitronectin is an abundant plasma 
protein, and it is released from platelets during the acute-
phase response.38 It is involved in the regulation of the coagu-
lation, complement, and fibrinolytic systems, as well as that 
of cell differentiation, proliferation, and morphogenesis.76 
Vitronectin is also an anticoagulant GAG neutralizer.77 The 
main consequence of GAG–vitronectin association is to allow 
the binding of a ternary complex composed of vitronectin, 
thrombin, and antithrombin to cell surface proteoglycans to 
facilitate internalization and degradation of the complex.77 
In disease, the increased concentration of vitronectin would 
increase this degradation and thus decrease thrombin and anti-
thrombin availability.
As with vitronectin, fibronectin is abundant in plasma and 
is a major component of the ESL.78 It is involved in numerous 
cellular processes, including development, organogenesis, cell 
adhesion and migration, hemostasis, angiogenesis, and vascu-
lar remodeling.78 Plasma fibronectin circulates in the blood in 
a compact conformation until it binds to endothelial GAGs.78 It 
then alters its structure to form an extended conformation that 
subsequently assembles into fibrils.78 A consequence of this 
binding is that plasma fibronectin interferes with antithrom-
bin binding to immobilized LMWH; however, antithrombin 
is only completely displaced from heparin at fibronectin/anti-
thrombin ratios greater than those found physiologically.39,79 
On the other hand, the binding of injected heparin to endo-
thelium-bound fibronectin fibers induces a conformational 
change in fibronectin that increases its affinity for vascular 
endothelial growth factor.80
Fibrinogen is another abundant plasma protein and 
is the main protein responsible for the creation of blood 
clots. Fibrinogen binds to endothelial cells through surface 
proteoglycans, which facilitates clot formation.81 Heparin 
binding to this bound fibrinogen (to which they have a 
higher affinity than to free fibrinogen) then mitigates clot 
nucleation through the formation of a fibrinogen–hepa-
rin–thrombin ternary complex.81 As a consequence of this 
Figure 4. Representation of the key locations where circulatory glycosaminoglycans (GAG)-neutralizing proteins/molecules are derived. 
Numerous proteins normally bind to endothelial GAGs. They are displaced by injection of heparin. Several key neutralizing molecules are 
also found in the plasma. Activated platelets and neutrophils can also release such proteins through exocytosis of granular vesicles. Dam-
aged cells expressing dermatan sulfate–containing proteoglycans also release GAG-neutralizing molecules.
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Table 3. General Properties of Important GAG-Binding Proteins Including Their Functions, Where They Are Synthesized and Stored, When 
They Are Released, Their Plasma Concentration, and Specific Information on the Abilities of These Proteins to Bind Particular GAGs
Protein Size, kDa Function Cell/Tissue Expression Localization Normal Plasma Conc.
GAG-Binding 
Specificity
FGF7 28 Growth factor (epithelial 
cells)
Mesenchymal cells of 
parenchymal organs
Plasma (upregulated in 
response to injury)
643 pmol/L34 Heparin; HS; DS
FGF1 17.46 Growth factor 
(endothelial cells), 
angiogenesis
Brain, kidney and heart Plasma 28–48 pmol/L35 Heparin; HS; DS
Heparin affin 
regulatory peptide
15.3 Growth factor (neurite 
outgrowth in embryos 
and tissue development)
At the surface of cells Plasma (released locally 
on injury)
33 pmol/L32 Heparin; HS; DS
PF4 7.8 Coagulation Megakaryocytes Platelet α-granules; 
plasma (secreted during 
coagulation)
0.256–1.28 nmol/L,36 









2.67–5.33 μmol/L38 Heparin (+AT 
sequence or + 
cleavage sequence); 
not DS




activation and wound 
healing
Liver Platelet α-granules; 
plasma (secreted during 
coagulation)
300–600 nmol/L39 Heparin (+AT 
sequence); HS; DS
Fibrinogen 340 Coagulation (form fibrin 
clot)
Liver Platelet α-granules; 
plasma (secreted during 
coagulation)
12–24 μmol/L40 Heparin; DS
HRG 75 Angiogenesis, immunity, 
coagulation, fibrinolysis
Liver Platelet α-granules; 
plasma (secreted during 
coagulation)





120 Coagulation (intrinsic 
pathway of coagulation 
cascade)
Mostly in the liver but 
also endothelial cells 
and neutrophils
Platelet α-granules; 
plasma (secreted during 
coagulation)
1–2 μmol/L43 Heparin (±AT 
sequence); HS
Serum amyloid P 
protein
25 Not fully known, 




Liver Plasma 1.6 μmol/L44 Heparin; HS; DS
Kallistatin 58 Coagulation (serpin, 
inhibits kallikrein)
Mostly in the liver but 
also in the kidneys, 




380 nmol/L45 Heparin; not HS or DS
Lactoferrin 80 Inflammation Most mucosal 
secretions such as 
uterine fluid, vaginal 
secretion, seminal fluid, 
saliva, bile, pancreatic 
juice, small intestine 
secretions, nasal 
secretion, and tears; 
milk; myeloid tissue
Secondary granules 





and excessive iron 
intake)

















response and ≤10 fold 
in response to injury, 
infection, pregnancy)
10–33 μmol/L48 Does not bind GAG 
but thrombin and FXa
(continued )
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binding, fibrinogen is also involved in anticoagulant GAG 
neutralization. The direct study of fibrinogen-mediated 
GAG neutralization is complicated by the fact that throm-
bin cleaves fibrinogen into fibrin. Yet, fibrinogen is known 
to be more effective at neutralizing DS than both PF4 and 
histidine-rich glycoprotein (HRG).58 This neutralization 
occurs at physiological fibrinogen concentrations, and the 
mechanism seems not to be through direct competition for 
DS binding but by modulating the rate of formation of the 
thrombin–HCII complex.58 Fibrin can form complexes with 
heparin, antithrombin, and thrombin to reduce thrombin 
inhibition by antithrombin.59,60 Because of those interac-
tions, plasma fibrinogen levels are linked to heparin resis-
tance in patients.82
In addition to those proteins, both Ca2+ and Zn2+ are 
released from activated platelets, and they can also affect the 
activity of GAGs.83 The role of Zn2+ in the neutralization is 
particularly interesting as the concentration of labile Zn2+ in 
plasma can be directly influenced by free fatty acid levels in 
plasma through a switch on human serum albumin, the main 
plasma transporter for both Zn2+ and free fatty acids.84,85 This 
dynamic may be important for individuals with diabetes mel-
litus,86 obesity,87 and cancer88 who typically associate with 
higher plasma free fatty acids levels and have a higher inci-
dence of developing thrombotic complications.89 This is fur-
ther supported by a study suggesting that higher doses of UFH 
are required in diabetic versus nondiabetic individuals.90
GAG Neutralization During Inflammation
Inflammation and coagulation are processes that are closely 
linked because such inflammatory proteins often come into 
contact with GAGs and can influence their anticoagulant activ-
ity. Some proteins even play a dual role in both processes, as 
is the case of HRG, a key adaptor protein released by platelets 
that regulates angiogenesis, immune functioning, and coag-
ulation.91,92 HRG is the second most abundant HS-binding 
protein in plasma after antithrombin and binds endothelial 
HS in a Zn2+-dependent manner. HRG–GAG binding is thus 
enhanced at injury sites where platelets release Zn2+.62 This 
allows the protein to both neutralize anticoagulant GAGs and 
to provide a tether site on the ESL to facilitate interaction 
with ligands such as plasminogen.85,93 In addition, HRG can 
compete with FGF for binding to HS and thus mediate the 
mitogenic activity of growth factors.94 High-molecular-weight 
kininogen (HMWK) and serum amyloid P protein share simi-
lar heparin-neutralizing functions (and ligands-binding prop-
erties) to HRG and are present in plasma in similarly high 
concentrations.64,65 HMWK is involved in coagulation through 
the activation of factor XII. During this action, HMWK is 
cleaved by kallikrein into the peptide bradykinin, which plays 
a role in vasodilation.64 Serum amyloid P protein is involved 
in the innate immune system and in clearing cellular debris 
but also contributes to the progression of neurodegeneration 
through its interaction with amyloid fibers.44,95 HRG, HMWK, 
and serum amyloid P protein can all bind to polyanions such 
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AT indicates antithrombin; DS, dermatan sulfate; FGF, fibroblast growth factors; GAG, glycosaminoglycans; HRG, histidine-rich glycoprotein; HS, heparan sulfate; and 
PF4, platelet factor 4.
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as GAGs but also pathogens, anionic phospholipids (such as 
those exposed by dying cells), and DNA.94 For certain patho-
gens, this interaction can destabilize the membrane, leading 
to cell death or can reduce their pathogenicity through incor-
poration of the organisms inside fibrin clots.94 Similarly, HRG 
can also tether IgG to necrotic cells through binding to spe-
cific phospholipids at their surface and thus facilitate their 
phagocytosis.96 Binding of HMWK to polyanionic surface 
exposed by damaged cells also activates the kallikrein coagu-
lation pathway.94
Lactoferrin is a low abundance (<19 nmol/L) iron-binding 
plasma protein stored in neutrophils.97,98 It can increase in con-
centration up to 3-fold during severe infection, autoimmune 
disease, or pregnancy, in addition to a local increase at the site 
of infection.47 It has been shown to bind and neutralize hepa-
rin in a dose-dependent manner, and its activity is comparable 
to that of PF4.66,99 However, this interaction can outcompete 
the binding of pathogens at the cell surface, preventing cell 
entry and stopping infection at an early stage.100 Thus, lacto-
ferrin displaced by exogenous heparin administration has the 
potential to negate this activity and leave the organism more 
vulnerable to infection. Another inflammation-associated 
protein is alpha-1-acid glycoprotein, an acute-phase protein 
responsible for modulating the immune response. It inhibits 
platelet aggregation and is an important plasma drug carrier 
involved in transporting heparin.48 Alpha-1-acid glycoprotein 
is abundant in plasma and is upregulated in certain disease 
states (liver cancer, HIV infection), drug use, or pregnancy. In 
addition to its basal concentration in plasma, it is also secreted 
locally by activated neutrophils.48 Within the ESL, it plays an 
important role in maintaining capillary permeability.101 Alpha-
1-acid glycoprotein can neutralize heparin but only when 
present at high concentrations, such as those that occur dur-
ing inflammation.67,68 An injection of heparin could potentially 
saturate the transport site on the protein and prevent it from 
carrying other drugs or molecules.
Histones are usually associated with DNA inside cell 
nuclei but are released into plasma by activated inflamma-
tory cells (to form neutrophil extracellular traps) and after 
cell death.49 They are mediators of cytotoxicity and sepsis 
during which their plasma concentration increases signifi-
cantly.102 Histones have various procoagulatory activities 
(activation of platelets, stimulation of thrombin generation, 
and promotion of von Willebrand factor release), which 
include the ability to neutralize heparin.69 As a conse-
quence, heparin–histone binding interferes with formation 
of neutrophil extracellular traps and perturbs venous throm-
bosis.103 Histones, however, bind more readily to other poly-
anions. Its interaction with polysialic acid, for example, is 
important in the development and regeneration of the ner-
vous system.104,105
Although not strictly a GAG-neutralizing protein, kal-
listatin is a GAG-binding serpin. The binding of GAG pre-
vents kallistatin from binding and inhibiting kallikrein, thus 
allowing activation of factor XII and cleavage of HMWK 
into bradykinin. Both events result in antiangiogenic and 










FGF7 Yes*31 Unknown Unknown Unknown
FGF1 Yes*31 Unknown Unknown Unknown
Heparin affin regulatory peptide Yes32 Yes32 Unknown Unknown
Platelet factor 4 Yes*36,52,53 Yes54 Yes55 Yes55
Vitronectin Yes*56,57 Unknown No58 No58
Fibronectin Yes*†39 Unknown Unknown Unknown
Fibrinogen Yes59,60 Unknown Unknown Yes58
HRG Yes*61 Yes†‡61,62 Yes55,58,63 Yes‡55,58,63
High-molecular-weight kininogen Yes*64 Unknown Unknown Unknown
Serum amyloid P protein Yes65 Unknown Yes65 Yes65
Lactoferrin Yes66 Unknown Unknown Unknown
Alpha-1-acid glycoprotein Yes67,68 Unknown Unknown Unknown
Histones Yes*69 Unknown Unknown Unknown
Low-density lipoprotein Yes70 Unknown Unknown Unknown
Tissue factor Yes71 Unknown Unknown Unknown
Activated factor VII Yes*72,73 Unknown Unknown Unknown
Slit3 Yes74 Unknown Unknown Unknown
AT indicates antithrombin; FGF, fibroblast growth factors; HCII, heparin cofactor II; HRG, histidine-rich glycoprotein; HS, heparan sulfate; and LMWH, 
low-molecular-weight heparin.
*Full or partial neutralization of LMWHs.
†Excess protein is needed for full neutralization.
‡Weak neutralization.
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procoagulatory effects.45,106 An important consequence of 
this is that competition between kallistatin and vascular 
endothelial growth factor and bFGF for endothelial GAG 
binding reduces the angiogenic effects associated with these 
molecules.106
Other Molecules That Can Neutralize GAGs
Lipoproteins are macromolecular complexes made up of lip-
ids and protein. Depending on their size, they are classified 
as chylomicrons, very-low-density lipoproteins, intermedi-
ate-density lipoproteins, low-density lipoproteins, and high-
density lipoproteins.107 In the blood, they are involved in the 
transport of cholesterol, triglycerides, and fat-soluble vita-
mins.107 They are therefore present in the blood and interact 
easily with GAGs. Low-density lipoproteins form insoluble 
complexes with heparins.108,109 Very-low-density lipopro-
teins have a similar but reduced effect on heparin while 
high-density lipoproteins do not neutralize heparin.70 The 
binding of lipoproteins to endothelial proteoglycans and the 
subsequent inflammatory responses could potentially have 
important consequences in the initiation and progression of 
the atherosclerotic process.13 Other proteins have also been 
shown to neutralize heparin (tissue factor,71 factor VII,72,73 
and the axon guidance protein, Slit374); however, their low 
concentrations make them unlikely to play a major role in 
endogenous neutralization.
Breakdown or Downregulation of GAGs
In addition to their neutralization, heparin, HS, and DS can be 
prevented from exercising their anticoagulant actions through 
either a reduction in synthesis or through targeted degrada-
tion. Homocysteine, a compound generated during amino 
acid synthesis, is an important regulator of GAG synthesis.110 
Its main action is to inhibit the protein C anticoagulant path-
way by decreasing the thrombomodulin pool at the surface 
of endothelial cells and reducing protein C activation.111 In 
addition, homocysteine has been shown to diminish the syn-
thesis of anticoagulant HS at the surface of endothelial cells, 
thus also reducing the antithrombin-binding HS pool.111 This 
process occurs at a slower rate than the inhibition of protein 
C and does not directly influence HS already present at the 
surface of the cells. To enable inhibition of HS synthesis, the 
homocysteine concentration needs to be around 100 μmol/L. 
This concentration can be achieved in vivo but only in certain 
disease states (eg, genetic polymorphisms in MTHFR—the 
gene encoding methylenetetrahydrofolate reductase, which is 
required for homocysteine synthesis) and in severe nutritional 
deficiency.110,111 However, a concentration of 10 µmol/L may 
be sufficient if the redox potential of the cell is influenced by 
other factors, for example, by the presence of certain cations 
such as Cu+, Cu2+, Fe2+, or Fe3+.110,111 Such elevated homo-
cysteine levels are associated with cardiovascular diseases, 
disorders associated with abnormal renal function, adminis-
tration of certain lipid-lowering drugs, and also caffeine or 
alcohol consumption.110,111
More directly, anticoagulant GAGs can be degraded by 
lyases (heparinases) or hydrolases (heparanases and elas-
tases). Such enzymes are released during inflammation from 
macrophages after they are activated. These include cathepsin 
S, which can directly hydrolyse GAGs.112 Antithrombin and 
HCII can also be cleaved by neutrophil elastase or by cathep-
sin G. These enzymes are present in the primary granules 
of neutrophils and are released during inflammation. Their 
cleavage of antithrombin and HCII is enhanced by the pres-
ence of GAGs.113–115
Summary and Clinical Impacts
There are multiple proteins that impact on coagulation via 
GAG neutralization to a degree which is not fully appreci-
ated. These include proteins involved in control of inflam-
mation, lipid transport, and cellular communication. In 
addition, most of the molecules that bind GAGs (many 
of which were not highlighted in this review) in vitro are 
unlikely to do so under physiological conditions where 
protein interactions are more complex (ie, presence of mul-
tiple interacting partners, formation of ternary complexes). 
Clarification of which GAG-binding proteins are relevant 
in vivo is thus still required. Details of the neutralization 
mechanisms involving HS and DS are lacking. Binding and 
neutralization of cell-associated HS and DS by proteins are 
more complex to study than with heparin, and this difficulty 
has likely limited the information available on their inter-
actions with proteins. Furthermore, many studies examin-
ing GAG–protein interactions have focused on the resultant 
impact on other physiological processes and not coagula-
tion, and so further studies are required to uncover specific 
roles in neutralization of anticoagulant GAGs. Finally, the 
relevance of endogenous heparin to physiological coagula-
tion control is still controversial as genetic studies support-
ing its lack of importance (NDST2 knockout mice) did not 
specifically analyze clot parameters.21,22
It is clear that the wide range of proteins that influence 
the anticoagulant properties of GAGs will affect a patients’ 
response to particular forms of heparin or heparin-based 
drugs. Indeed, levels of GAG-neutralizing proteins are influ-
enced by an individual’s genetics, age, diet, and disease state. 
In a clinical context, this makes the dose–response profiles 
of heparins and heparin-based drugs difficult to predict. 
Knowing more about endogenous molecules that bind to 
GAGs and those that regulate their turnover will enable a bet-
ter understanding of clotting disorders and treatment choices. 
Personalized treatments taking into consideration the plasma 
levels of a particular neutralizing protein may also be consid-
ered. In addition, it is important to take those information into 
account when dealing with specific disorders such as heparin-
induced thrombocytopenia or pathologically high zinc plasma 
levels. More trials are needed in this area to better understand 
the advantages and drawbacks of each GAG when given to 
particular subsets of patients. Current guidelines also vary 
widely between regions. Consistency and better application 
of these guidelines is required by hospitals to provide a bet-
ter care to patients. New knowledge gained by studying GAG 
neutralization will also aid the development and application 
of new clinical heparin neutralizers. Indeed, as protamine 
sulfate treatment is known to cause several adverse effects, 
including anaphylaxis, hypertension, nausea/fatigue, and 
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back pain,27 other proteins or molecules including heparin-
binding synthetic peptides are already being trialed as poten-
tial replacements.4
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Highlights
• The glycosaminoglycans, heparan sulfate, dermatan sulfate, and heparin are important anticoagulants that inhibit clot formation through 
interactions with antithrombin and heparin cofactor II.
• Unfractionated heparin, low-molecular-weight heparin, and heparin-derived drugs are used clinically to treat coagulatory disorders.
• A wide range of proteins have been reported to bind and neutralize glycosaminoglycans, as reviewed here.
• The anticoagulant activity of glycosaminoglycans may also be regulated through inhibition of synthesis or by degradative enzymes during 
inflammatory processes.
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